<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thyroid storm</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thyroid storm</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thyroid storm</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thyroid storm is a rare, life-threatening condition characterized by severe clinical manifestations of thyrotoxicosis [<a href="#rid1">1</a>]. In national surveys from the United States and Japan, the incidence of thyroid storm was 0.57 to 0.76 and 0.20 per 100,000 persons per year, respectively, and 4.8 to 5.6 per 100,000 hospitalized patients per year [<a href="#rid2">2-4</a>]. In the United States survey, 16 percent of inpatients with thyrotoxicosis were diagnosed with storm [<a href="#rid4">4</a>]. It may be precipitated by abrupt discontinuation of antithyroid drugs or by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, an acute iodine load, or parturition. In addition to specific therapy directed against the thyroid, supportive therapy in an intensive care unit (ICU) and recognition and treatment of any precipitating factors is essential since the mortality rate of thyroid storm is substantial (10 to 30 percent) [<a href="#rid2">2,5-9</a>].</p><p>The clinical manifestations, diagnosis, and management of thyroid storm will be reviewed here. The general topic of hyperthyroidism (without thyroid storm), including diagnosis, causes, and treatment, is reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7884.html" rel="external">"Hyperthyroidism during pregnancy: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H15056150"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Although thyroid storm can develop in patients with longstanding untreated hyperthyroidism (Graves' disease, toxic multinodular goiter, solitary toxic adenoma), it is often precipitated by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, an acute iodine load (including <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> use), or parturition. In addition, irregular use or discontinuation of antithyroid drugs and poor access to health care are commonly reported precipitants of thyroid storm [<a href="#rid2">2-5,8,10,11</a>]. Appropriate preoperative preparation of hyperthyroid patients undergoing nonthyroidal surgery or thyroidectomy for hyperthyroidism has led to a dramatic reduction in the prevalence of surgically induced thyroid storm [<a href="#rid12">12</a>].</p><p>It is unclear why certain factors result in the development of thyroid storm. Hypotheses include a rapid rate of increase in serum thyroid hormone levels, increased responsiveness to catecholamines, or enhanced cellular responses to thyroid hormone [<a href="#rid1">1</a>]. The degree of thyroid hormone excess (elevation of thyroxine [T4] and triiodothyronine [T3], suppression of thyroid-stimulating hormone [TSH]) typically is not more profound than that seen in patients with uncomplicated thyrotoxicosis. However, one study found that while the total T4 and T3 levels were similar to those seen in uncomplicated patients, the free T4 and T3 concentrations were higher in patients with thyroid storm [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H15056278"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with severe and life-threatening thyrotoxicosis typically have an exaggeration of the usual symptoms of hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="headingAnchor" id="H57436952"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Cardiovascular symptoms in many patients include tachycardia to rates that can exceed 140 beats/minute and congestive heart failure. Hypotension, cardiac arrhythmia, and death from cardiovascular collapse may occur [<a href="#rid14">14</a>]. In one series of 28 cases, cardiac manifestations were predominant, with &gt;60 percent having severe tachycardia and/or atrial fibrillation [<a href="#rid5">5</a>].</p><p>Hyperpyrexia to 104 to 106°F is common. Agitation, anxiety, delirium, psychosis, stupor, or coma are also common and are considered by many to be essential to the diagnosis. In one series, altered mentation was the only clinical finding that distinguished "storm" from "compensated" hyperthyroidism [<a href="#rid6">6</a>], and in another series, it was statistically associated with mortality [<a href="#rid5">5</a>]. In a retrospective study from Japan, older age &gt;60 years, central nervous system dysfunction, requirement of mechanical ventilation, and nonuse of antithyroid drugs or beta blockers were associated with higher mortality [<a href="#rid7">7</a>]. Other symptoms may include severe nausea, vomiting, diarrhea, abdominal pain, or hepatic failure with jaundice.</p><p>Physical examination may reveal goiter, ophthalmopathy (in the presence of Graves' disease), lid lag, hand tremor, and warm and moist skin.</p><p class="headingAnchor" id="H57436958"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>All patients with overt primary hyperthyroidism (including patients with thyroid storm) have low TSH and high free T4 and/or T3 concentrations. The degree of thyroid hormone excess in thyroid storm is typically not more profound than that seen in patients with uncomplicated thyrotoxicosis. Other laboratory findings in patients with thyrotoxicosis (with or without thyroid storm) may include [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild hyperglycemia (secondary to a catecholamine-induced inhibition of insulin release and increased glycogenolysis)</p><p class="bulletIndent1"><span class="glyph">●</span>Mild hypercalcemia (secondary to hemoconcentration and enhanced bone resorption)</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal liver function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytosis or leukopenia</p><p></p><p class="headingAnchor" id="H13827326"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of thyroid storm is based upon the presence of severe and life-threatening symptoms (hyperpyrexia, cardiovascular dysfunction, altered mentation) in a patient with biochemical evidence of hyperthyroidism (elevation of free T4 and/or T3 and suppression of TSH).</p><p>There are no universally accepted criteria or validated clinical tools for diagnosing thyroid storm. In 1993, Burch and Wartofsky introduced a scoring system using precise clinical criteria for the identification of thyroid storm  (<a class="graphic graphic_table graphicRef60908" data-inline-graphics="60908" href="/d/graphic/60908.html" rel="external">table 1</a>) [<a href="#rid16">16</a>]. A score of 45 or more is highly suggestive of thyroid storm, whereas a score below 25 makes thyroid storm unlikely. A score of 25 to 44 is suggestive of impending storm. While this scoring system is likely sensitive, it is not very specific. For example, a mildly hyperthyroid patient with influenza, a fever, and nausea could score high enough to meet the criteria for storm. Another diagnostic system based upon similar clinical findings (central nervous system manifestations, fever, tachycardia, congestive heart failure, gastrointestinal manifestations) has been proposed [<a href="#rid2">2</a>], but this latter system may have reduced sensitivity for making the diagnosis [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thyroid function tests</strong> – Thyroid function tests (TSH) should be assessed in all patients in whom there is a clinical suspicion of thyroid storm (hyperpyrexia with temperature &gt;103°F [39.4°C], goiter, cardiovascular dysfunction, altered mentation, atrial fibrillation, history of antithyroid drug therapy for hyperthyroidism, recent thyroid or nonthyroidal surgery, recent exposure to iodine-containing contrast). If the TSH is below normal, free T4 and T3 should be measured. The degree of hyperthyroidism (elevation of T4 and/or T3 and suppression of TSH) in patients with thyroid storm is, in general, comparable with that in patients with uncomplicated overt hyperthyroidism. Thus, the degree of hyperthyroidism is not a criterion for diagnosing thyroid storm. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Determining the etiology</strong> – Determining the etiology of thyrotoxicosis in patients with thyroid storm should not delay prompt treatment of patients with clinical manifestations of thyroid storm. (See <a class="local">'General principles'</a> below.)</p><p></p><p class="bulletIndent2">Most patients with thyroid storm have Graves' disease, and some have toxic adenoma or toxic multinodular goiter. In a multicenter study from France, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> use was the most common precipitating factor [<a href="#rid8">8</a>]. A destructive thyroiditis associated with the use of checkpoint inhibitors in compromised oncology patients may rarely be associated with thyroid storm [<a href="#rid17">17</a>]. Measuring thyrotropin receptor antibodies (TRAb) or determining a radioiodine uptake can distinguish Graves' disease from other causes of hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Determining the etiology'</a> and  <a class="medical medical_review" href="/d/html/7834.html" rel="external">"Amiodarone and thyroid dysfunction", section on 'Hyperthyroidism'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The therapeutic options for thyroid storm are expanded from those used for uncomplicated hyperthyroidism, with additional drugs often used such as glucocorticoids and an iodine solution, and the standard drugs are given in higher doses and with more frequent dosing.</p><p class="headingAnchor" id="H15056520"><span class="h2">General principles</span><span class="headingEndMark"> — </span>The principles of treatment outlined below are based upon clinical experience and case studies since there are no prospective studies. They are frequently also applied to patients with severe hyperthyroidism who do not fully meet the criteria for thyroid storm. The therapeutic regimen typically consists of multiple medications, each of which has a different mechanism of action [<a href="#rid15">15,18,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A beta blocker (if not contraindicated) to control the symptoms and signs induced by increased adrenergic tone</p><p class="bulletIndent1"><span class="glyph">●</span>A thionamide to block new hormone synthesis</p><p class="bulletIndent1"><span class="glyph">●</span>An iodine solution to block the release of thyroid hormone</p><p class="bulletIndent1"><span class="glyph">●</span>An iodinated radiocontrast agent (not available in the United States) to inhibit the peripheral conversion of T4 to T3</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids to reduce T4-to-T3 conversion, promote vasomotor stability, possibly reduce the autoimmune process in Graves' disease, and possibly treat an associated relative adrenal insufficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid sequestrants may also be of benefit in severe cases to decrease enterohepatic recycling of thyroid hormones</p><p></p><p>Full support of the patient in an intensive care unit (ICU) is essential since the mortality rate of thyroid storm is substantial [<a href="#rid2">2,5-8</a>]. In two series of patients with thyroid storm (patients seen between 2006 and 2013), mortality was 8 percent in a Los Angeles hospital and 25 percent in a Singapore hospital [<a href="#rid5">5,6</a>]. In a French series (patients seen between 2000 and 2017), mortality was 17 percent in the ICU and 22 percent six months after hospital admission [<a href="#rid8">8</a>].</p><p>Recognition and treatment of any precipitating factors (eg, infection), in addition to specific therapy directed against the thyroid, may be critical to the final outcome. Many patients require substantial amounts of fluid (eg, 3 to 5 liters a day), while others may require diuresis because of congestive heart failure. Medication requirements (eg, beta blocker, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>) may be quite high because of increased drug metabolism as a result of hyperthyroidism. Infection needs to be identified and treated, and hyperpyrexia should be aggressively corrected. <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> should be used instead of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> since the latter can increase serum free T4 and T3 concentrations by interfering with their protein binding. The use of cooling blankets and ice packs should be considered in patients with persistent fever.</p><p>For most patients with clinical features of <strong>thyroid storm</strong> or with <strong>impending storm</strong> (ie, severe thyrotoxicosis that does not fully meet the criteria for thyroid storm), we begin immediate treatment with:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blocker</strong> – <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">Propranolol</a> preferred. (See <a class="local">'Beta blockers'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thionamide</strong> – <a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">Propylthiouracil</a> (PTU) preferred.<strong> </strong>(See <a class="local">'Thionamides'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iodine</strong> – Saturated solution of potassium iodide (SSKI) or Lugol's solution. (See <a class="local">'Iodine'</a> below.)</p><p></p><p>For patients with clinical features of <strong>thyroid storm</strong>, we also administer:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydrocortisone</strong> – (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p><a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">Cholestyramine</a> is an additional adjunctive therapy, especially if the patient is allergic to thionamides. (See <a class="local">'Other therapies'</a> below.)</p><p>Initial therapy is adjusted after there is evidence of clinical improvement. (See <a class="local">'Subsequent management'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>For most patients with thyroid storm or severe thyrotoxicosis, we begin immediate treatment with a beta blocker (typically <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>) in a dose to achieve adequate control of heart rate and blood pressure.</p><p>Although control of tachycardia may lead to improvement in cardiac function (if heart rate is an exacerbating factor), beta blockers (oral or intravenous) are contraindicated in patients with acute decompensated heart failure with systolic dysfunction. The hyperadrenergic state is important for maintaining cardiac output. In this setting, a beta blocker-induced reduction in heart rate could lead to profound hypotension [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations", section on 'Treatment goals for acute versus chronic HF'</a>.)</p><p>Beta blockers should be used with caution in patients who have asthma, chronic obstructive pulmonary disease, or severe peripheral vascular disease. In patients with reactive airways disease, cardioselective beta blockers such as <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> or <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> could be considered, but this should be done carefully. In some patients with severe asthma in whom beta blockers might be contraindicated, rate control can be achieved with calcium channel blockers such as <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Propranolol</strong> – We use <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> for initial therapy because in high doses it inhibits the conversion of T4 to T3 by inhibiting the type 1 deiodinase [<a href="#rid23">23</a>]. The dose of propranolol is titrated to achieve adequate control of heart rate, typically 60 to 80 mg orally every four to six hours, with appropriate adjustment for heart rate and blood pressure. It can also be given intravenously or via a nasogastric tube. Intravenous administration should only be done in a setting where hemodynamics can be monitored. The intravenous dose of propranolol is 0.5 to 1 mg over 10 minutes followed by 1 to 2 mg over 10 minutes every few hours [<a href="#rid16">16,24</a>]. Higher doses may occasionally be required, but care should be taken to avoid hypotension and aggravation of existing heart failure.</p><p></p><p class="bulletIndent1">When transitioning from intravenous to oral/nasogastric treatment, intravenous therapy may need to be continued until adequate effectiveness of the oral/nasogastric treatment is ascertained.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Esmolol</strong> – The Japanese guidelines recommend the short-acting intravenous beta blocker (eg, <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>) over <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> because of increased mortality in patients with heart failure treated with propranolol [<a href="#rid25">25</a>]. Esmolol may be a reasonable option if it is uncertain that a beta blocker will be tolerated since after discontinuation, duration of action is very short. It must be administered in a monitored setting.</p><p></p><p class="bulletIndent1">Recommended published doses include a loading dose of 250 to 500 mcg/kg, followed by an infusion at 50 to 100 mcg/kg per minute [<a href="#rid26">26</a>], or, in the Japanese guidelines, a loading dose of 1 mg/kg over 30 seconds followed by approximately 150 mcg/kg/minute [<a href="#rid25">25</a>]. The dose is adjusted based on the heart rate. These regimens permit rapid up- or down-titration of the drug to achieve adequate beta blockade while minimizing adverse reactions. (See  <a class="medical medical_review" href="/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Thionamides</span><span class="headingEndMark"> — </span>For patients with thyroid storm or severe thyrotoxicosis, we begin immediate treatment with either PTU or <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> [<a href="#rid27">27</a>]. Carbimazole, a third drug that is metabolized to methimazole, is available in many countries but not in North America. Thionamides block de novo thyroid hormone synthesis within one to two hours after administration. However, they have no effect on the release of preformed hormone from the thyroid gland. (See  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a>.)</p><p class="headingAnchor" id="H3995430653"><span class="h3">Choice of thionamide</span></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest PTU for the acute treatment of life-threatening thyroid storm in an ICU setting, where it can be administered regularly every four hours. PTU is favored over <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> because of PTU's effect to decrease T4-to-T3 conversion. T3 levels drop by approximately 45 percent within 24 hours after PTU but only 10 to 15 percent within 24 hours after methimazole [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1">Patients started on PTU in the ICU should be transitioned to <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> before discharge from the hospital. (See <a class="local">'Subsequent management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">Methimazole</a> may be preferred for severe (but not life-threatening) hyperthyroidism because methimazole has a longer duration of action and, after weeks of treatment, results in more rapid normalization of serum T3 compared with PTU. In addition, the frequency of hepatotoxicity may be less with methimazole. (See  <a class="medical medical_review" href="/d/html/7875.html" rel="external">"Thionamides: Side effects and toxicities"</a>.)</p><p></p><p class="bulletIndent1">In Japan, <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> is preferred over PTU, and in a retrospective study of 356 patients, there was no difference in mortality or disease severity in patients receiving methimazole or PTU [<a href="#rid25">25,30</a>].</p><p></p><p class="headingAnchor" id="H2907017497"><span class="h3">Initial dosing and administration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PTU</strong> – The dose of PTU is 200 to 250 mg every four hours. We do not typically administer a loading dose of PTU since the initial dose is generally adequate to block thyroid hormone synthesis. The American Thyroid Association (ATA) guidelines suggest a loading dose of 500 to 1000 mg [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methimazole</strong> – The dose of <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> is 20 mg orally every four to six hours.</p><p></p><p>The dose of thionamide given to patients with thyroid storm is likely higher than that required to completely block thyroid hormone synthesis. Both the substantial mortality associated with thyroid storm and the possibility of poor absorption because of concurrent gastrointestinal dysfunction have been used to justify the higher dose. Lower doses are used in patients with severe thyrotoxicosis who do not meet criteria for thyroid storm. (See  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Dosing'</a>.)</p><p>Both drugs are administered orally or, if need be, can be given via a nasogastric tube. The drugs can also be suspended in liquid or made up as a suppository or retention enema for rectal administration, which should be ordered well in advance from the pharmacy  (<a class="graphic graphic_table graphicRef79245" href="/d/graphic/79245.html" rel="external">table 2</a>) [<a href="#rid15">15,31-34</a>]. In one study comparing the use of an enema versus a suppository preparation of PTU, 15 patients with newly diagnosed hyperthyroidism were randomly assigned to a PTU enema (eight 50 mg tablets of PTU were dissolved in 90 mL of sterile water) versus two PTU suppositories (200 mg of PTU were dissolved in a polyethylene glycol base and put into each suppository) [<a href="#rid34">34</a>]. The enema form provided better bioavailability than the suppository form (time to peak level 85 versus 172 minutes, maximum peak level 3.89 versus 2.01 mcg/mL). However, both preparations proved to have comparable therapeutic effect, as measured by a significant decrease in serum free T3 levels. </p><p>For patients intolerant of oral or rectal thionamides, intravenous <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> is available in some countries (eg, Japan) but not in the United States. In a case study, United States Pharmacopeia (USP) methimazole powder was prepared for intravenous administration (using aseptic technique) for two patients intolerant of oral or rectal administration [<a href="#rid35">35</a>]. In this setting, routine pharmacologic sterility tests are required as dictated by individual hospitals.</p><p class="headingAnchor" id="H73020135"><span class="h3">Patients unable to take a thionamide</span><span class="headingEndMark"> — </span>Although thionamide toxicity is uncommon, some patients are unable to continue thionamides because of rare side effects (such as agranulocytosis or hepatotoxicity) or because of allergy. Thyroid storm has been reported in patients with Graves' disease after discontinuation of thionamides (due to agranulocytosis or hepatotoxicity) [<a href="#rid36">36,37</a>]. In such patients who require urgent treatment of hyperthyroidism, thyroidectomy is the treatment of choice (see  <a class="medical medical_review" href="/d/html/7880.html" rel="external">"Surgical management of hyperthyroidism", section on 'Preoperative preparation'</a>). However, in a critically ill patient with a history of a severe reaction to one thionamide (eg, agranulocytosis or hepatotoxicity), who is too unstable for urgent thyroidectomy, cautious use of the alternate drug could be considered for one to two weeks with close monitoring of granulocyte counts/hepatic function tests.</p><p>Patients who are to undergo surgery require preoperative treatment of thyrotoxicosis. We typically treat with beta blockers (if not contraindicated, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> in a dose to achieve adequate control of heart rate, typically 60 to 80 mg every four to six hours), glucocorticoids to inhibit conversion of T4 to T3 (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, 1 to 2 mg every six hours), bile acid sequestrants (eg, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> 4 g orally four times daily) to reduce enterohepatic circulation of thyroid hormone, and, in patients with Graves' disease, iodine (SSKI, 5 drops [20 drops/mL, 50 mg iodide/drop] orally every six hours or Lugol's solution, 10 drops [20 drops/mL, 6.25 mg iodine/drop] every eight hours) [<a href="#rid38">38,39</a>].</p><p>Optimum preoperative treatment with iodine is approximately 10 days; however, depending upon the clinical status of the patient and surgical availability, preoperative treatment for 5 to 14 days is reasonable. Surgery should not be delayed longer, because of a phenomenon called escape from the Wolff-Chaikoff effect. Large doses of exogenous iodine inhibit the organification of iodine in the thyroid gland (the Wolff-Chaikoff effect). However, this effect is transient. The iodide transport system is able to adapt to higher concentrations of iodine, allowing thyroid hormone synthesis to proceed, with potential exacerbation of thyrotoxicosis. (See  <a class="medical medical_review" href="/d/html/7844.html" rel="external">"Iodine-induced thyroid dysfunction"</a>.)</p><p>In case reports, when traditional therapy has not been successful, plasmapheresis has been used to prepare patients with thyroid storm for thyroid surgery (see <a class="local">'Other therapies'</a> below). Iodinated contrast agents have also been used to prepare hyperthyroid patients for urgent surgery, but they are no longer available in most countries. (See  <a class="medical medical_review" href="/d/html/7880.html" rel="external">"Surgical management of hyperthyroidism", section on 'Preoperative preparation'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Iodine</span><span class="headingEndMark"> — </span>For patients with thyroid storm or severe thyrotoxicosis, we administer SSKI or potassium iodide and iodine (Lugol's solution) <strong>one hour</strong> <strong>after</strong> the first dose of thionamide is taken. The administration of iodine should be delayed for at least one hour <strong>after</strong> thionamide administration to prevent the iodine from being used as substrate for new hormone synthesis in patients with toxic adenoma or toxic multinodular goiter (since the etiology of the thyrotoxicosis is frequently uncertain at the time of admission) [<a href="#rid15">15</a>]. When the etiology of thyroid storm is known to be toxic adenoma or toxic multinodular goiter, iodine should be used cautiously since the use of iodine can exacerbate hyperthyroidism if thionamide treatment is interrupted.</p><p>Iodine-containing solutions have traditionally been utilized for the treatment of thyroid storm since iodine blocks the release of T4 and T3 from the gland within hours. (See  <a class="medical medical_review" href="/d/html/7878.html" rel="external">"Iodine in the treatment of hyperthyroidism"</a>.)</p><p>Either SSKI <strong>or</strong> Lugol's solution maybe be administered [<a href="#rid19">19,33</a>]. These solutions can be irritating to the gastrointestinal tract and should be diluted in 240 mL or more of beverage or taken with food.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSKI</strong> – 5 drops (50 mg iodide/drop [0.05 mL]) orally every six hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lugol's solution</strong> – 10 drops (6.25 mg iodide/iodine per drop [0.05 mL]) orally three times daily</p><p></p><p>There is no standard intravenous iodide preparation. The iodine solution can be given rectally [<a href="#rid33">33</a>].  </p><p>Although iodine is typically well tolerated, local esophageal or duodenal mucosal injury and hemorrhage have been reported after oral administration of Lugol's solution (960 mg iodine/day) for the treatment of thyroid storm [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>For patients with clinical features of thyroid storm, we administer glucocorticoids (300 mg loading dose, then <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>, 100 mg intravenously every eight hours; <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> can be used as an alternative). In contrast, we do not routinely use glucocorticoids in patients with moderate to severe, but otherwise uncomplicated, hyperthyroidism.</p><p>Glucocorticoids reduce T4-to-T3 conversion. They may have a direct effect on the underlying autoimmune process (if the thyroid storm is due to Graves' disease) and in addition, treat potentially associated limited adrenal reserve [<a href="#rid42">42</a>]. Because of the high mortality rate of thyroid storm, their use is commonly recommended by experts, although data are limited, and there are no randomized trials comparing management of thyroid storm with or without glucocorticoids [<a href="#rid43">43,44</a>]. In a retrospective study based on a claims database (811 ICU admissions for thyroid storm between 2013 and 2017), 600 patients received glucocorticoids and 211 did not [<a href="#rid44">44</a>]. There was no change in hospital mortality or mortality 30 days after discharge. Glucocorticoid use was associated with increased use of insulin.</p><p>Tapering and discontinuing glucocorticoids after improvement is reviewed below. (See <a class="local">'Subsequent management'</a> below.)</p><p class="headingAnchor" id="H97910473"><span class="h2">Other therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cholestyramine</strong> – Thyroid hormones are metabolized in the liver, where they are conjugated with glucuronide and sulfate, and the conjugation products are excreted in the bile. Free thyroid hormones are released in the intestine and are reabsorbed. Bile acid sequestrants (eg, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> 4 g orally four times daily) have been found to reduce thyroid hormone levels in thyrotoxic patients by interfering with enterohepatic circulation and recycling of thyroid hormone [<a href="#rid45">45-47</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">Cholestyramine</a> can be a useful adjunctive therapy in patients with thyroid storm, particularly in patients who are intolerant of thionamides. Since cholestyramine can interfere with the absorption of oral medications, other drugs given orally should be given two hours before or two hours after cholestyramine administration [<a href="#rid45">45</a>]. Cholestyramine may be discontinued when clinical status improves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iodinated radiocontrast agents</strong> – Iodinated contrast agents previously used to treat hyperthyroidism are currently not available in the United States or in most other countries.</p><p></p><p class="bulletIndent1">Iopanoic acid and other iodinated radiocontrast agents used for oral cholecystography have been used to treat hyperthyroidism, but there are little published data on their efficacy in thyroid storm (see  <a class="medical medical_review" href="/d/html/7877.html" rel="external">"Iodinated radiocontrast agents in the treatment of hyperthyroidism"</a>). They are, however, potent inhibitors of T4-to-T3 conversion, and the release of iodine in pharmacologic quantities from these agents has the additional benefit of blocking thyroid hormone release. They have been extremely useful in treating severe hyperthyroidism and in preparing hyperthyroid patients for urgent surgery [<a href="#rid48">48,49</a>]. If available, these agents can be given to patients with severe hyperthyroidism at a dose of 0.5 to 1 g once daily.</p><p></p><p class="bulletIndent1">Because they are iodinated, they should be given at least one hour <strong>after</strong> the thionamide to prevent the iodine from being used as substrate for new hormone synthesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis</strong> – Plasmapheresis has been tried when traditional therapy has not been successful [<a href="#rid37">37,50-54</a>]. It is an option for patients who cannot tolerate thionamides and in patients who are being prepared for urgent thyroidectomy. Plasmapheresis removes cytokines, antibodies, and thyroid hormones from plasma [<a href="#rid52">52</a>]. In one case report, a woman with Graves' disease and methimazole-induced agranulocytosis developed thyroid storm after <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> was discontinued. Treatment with plasmapheresis resulted in marked improvement in thyrotoxicosis within three days, allowing thyroidectomy for definitive therapy [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">The effects of plasmapheresis are transient, lasting 24 to 48 hours [<a href="#rid37">37</a>]. In a series of three patients who had therapeutic plasma exchange for thyroid storm preoperatively, free T4 levels were reduced on average by 21 percent after each treatment and by 55 percent after four treatments [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lithium</strong> – <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> has also been given to acutely block the release of thyroid hormone. However, its renal and neurologic toxicity limit its utility. (See  <a class="medical medical_review" href="/d/html/7843.html" rel="external">"Lithium and the thyroid", section on 'Hyperthyroidism'</a>.)</p><p></p><p class="headingAnchor" id="H1687118"><span class="h1">SUBSEQUENT MANAGEMENT</span><span class="headingEndMark"> — </span>After there is evidence of clinical improvement (defervescence, resolution of central nervous system and cardiovascular manifestations), some medications can be discontinued and others reduced.</p><p class="bulletIndent1"><span class="glyph">●</span>Iodine therapy can be discontinued (unless a thyroidectomy is planned in the next 10 to 14 days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers can be withdrawn, but only after thyroid function tests have returned to normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids are tapered and discontinued. The pace of the glucocorticoid taper depends upon the clinical course of the patient; a slower taper is necessary in patients who had a prolonged intensive care unit (ICU) stay with longer duration of glucocorticoid treatment. Some patients may need testing of adrenal function prior to discontinuing glucocorticoids. (See  <a class="medical medical_review" href="/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">Propylthiouracil</a> (PTU), if given, should be switched to <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> once the T3 is declining and hospital discharge is anticipated. Methimazole is preferred because of its better safety profile and better compliance rates. When switching to methimazole, the initial dose is generally high, 30 to 40 mg daily in divided doses, depending on the patient's clinical status. The dose is then titrated down to maintain euthyroidism. It is important to provide patient education about the risk of abruptly discontinuing treatment. Monitoring, dosing, and duration of thionamide therapy are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Monitoring'</a>.)</p><p></p><p>In patients with Graves' disease, definitive therapy with radioiodine or thyroidectomy is important to prevent a recurrence of severe thyrotoxicosis. Individual patient factors may influence the choice of definitive therapy, and the selection of therapy should involve discussion of the values and preferences of the patient. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism", section on 'Approach to treatment'</a> and  <a class="medical medical_review" href="/d/html/7880.html" rel="external">"Surgical management of hyperthyroidism", section on 'Preoperative preparation'</a> and  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Clinical use'</a>.)</p><p class="headingAnchor" id="H13827637"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and risk factors</strong> – Thyroid storm is a rare, life-threatening condition characterized by severe or exaggerated clinical manifestations of thyrotoxicosis. Although thyroid storm can develop in patients with longstanding untreated hyperthyroidism (Graves' disease, toxic multinodular goiter, solitary toxic adenoma), it is often precipitated by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, an acute iodine load, or parturition. (See <a class="local">'Introduction'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with thyroid storm typically have an exaggeration of the usual symptoms of hyperthyroidism. The classical symptoms of thyroid storm include tachycardia, hyperpyrexia, central nervous system dysfunction (agitation, delirium, psychosis, stupor, or coma), and gastrointestinal symptoms (nausea, vomiting, abdominal pain). Physical examination may reveal goiter, ophthalmopathy (in the presence of Graves' disease), lid lag, hand tremor, and warm and moist skin. Thyroid function tests show hyperthyroidism (suppressed thyroid-stimulating hormone [TSH], elevated free thyroxine [T4] and triiodothyronine [T3]) generally comparable with that in patients with uncomplicated overt hyperthyroidism. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of thyroid storm is based upon the presence of severe and life-threatening symptoms (hyperpyrexia, cardiovascular dysfunction, altered mentation) in a patient with biochemical evidence of hyperthyroidism (elevation of free T4 and/or T3 and suppression of TSH). There are no universally accepted criteria or validated clinical tools for diagnosing thyroid storm. In one scoring system  (<a class="graphic graphic_table graphicRef60908" href="/d/graphic/60908.html" rel="external">table 1</a>), a score of 45 or more is highly suggestive of thyroid storm, whereas a score below 25 makes thyroid storm unlikely. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General principles</strong> – The therapeutic options for thyroid storm are expanded from those used for uncomplicated hyperthyroidism, with additional drugs typically used, such as glucocorticoids and iodine solution (eg, saturated solution of potassium iodide [SSKI]), and standard drugs are given in higher doses and more frequently. In addition to specific therapy directed against the thyroid, supportive therapy in an intensive care unit (ICU) and recognition and treatment of any precipitating factors is essential since the mortality rate of thyroid storm is substantial (10 to 30 percent). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medical therapy</strong> – For most patients with clinical features of thyroid storm, we begin immediate treatment with:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Beta blocker (if not contraindicated, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> in a dose to achieve adequate control of heart rate, typically 60 to 80 mg orally every four to six hours)</p><p class="bulletIndent3"><span class="glyph">-</span>Thionamide</p><p class="bulletIndent3"><span class="glyph">-</span>Glucocorticoids (eg, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> intravenously, 300 mg loading dose, then 100 mg every eight hours)</p><p></p><p class="bulletIndent2">One hour after a thionamide is given, we administer iodine (SSKI, 5 drops [20 drops/mL, 50 mg iodide/drop] orally every six hours; or Lugol's solution, 10 drops [20 drops/mL, 6.25 mg iodine/drop] every eight hours). Bile acid sequestrants (<a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, 4 g orally four times daily) may also be of benefit in severe cases, especially if the patient is allergic to thionamides, to decrease enterohepatic recycling of thyroid hormones. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of thionamide</strong> – For patients with life-threatening thyroid storm admitted to an ICU, we suggest <a class="drug drug_general" data-topicid="9830" href="/d/drug information/9830.html" rel="external">propylthiouracil</a> (PTU; 200 to 250 mg orally every four hours) rather than <a class="drug drug_general" data-topicid="9627" href="/d/drug information/9627.html" rel="external">methimazole</a> as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). PTU blocks T4-to-T3 conversion and results in lower serum T3 levels for the first several days of treatment. However, for severe, but not life-threatening, hyperthyroidism, methimazole (20 mg every four to six hours) may be preferred because of its longer half-life, lower frequency of hepatic toxicity, and because it ultimately restores euthyroidism more quickly than PTU. Patients initially treated with PTU should be transitioned to methimazole before discharge from the hospital. (See <a class="local">'Thionamides'</a> above and  <a class="medical medical_review" href="/d/html/7875.html" rel="external">"Thionamides: Side effects and toxicities"</a> and <a class="local">'Subsequent management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thionamide intolerance</strong> – For patients with contraindications to thionamides who require urgent correction of hyperthyroidism, surgery is the treatment of choice. Patients who are to undergo surgery require preoperative treatment of thyrotoxicosis. We typically treat with beta blockers (if not contraindicated, <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> 60 to 80 mg every four to six hours), glucocorticoids to inhibit conversion of T4 to T3 (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, 1 to 2 mg every six hours), bile acid sequestrants (eg, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> 4 g orally four times daily), and, in patients with Graves' disease, iodine (SSKI, 5 drops [50 mg iodide/drop] orally every six hours; or Lugol's solution, 10 drops [6.25 mg iodide/iodine per drop] every eight hours). Optimal preoperative treatment is approximately 10 days, but depending upon clinical considerations and surgical availability, 5 to 14 days of treatment with iodine preoperatively is reasonable. (See <a class="local">'Thionamides'</a> above and  <a class="medical medical_review" href="/d/html/7880.html" rel="external">"Surgical management of hyperthyroidism", section on 'Patients unable to take a thionamide drug'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent management</strong> – After there is evidence of clinical improvement (eg, defervescence, resolution of central nervous system and cardiovascular manifestations), some medications can be discontinued and others reduced. Long-term antithyroid therapy is required to prevent a recurrence of severe thyrotoxicosis. Individual patient factors may influence the choice of definitive therapy, and the selection of therapy should involve discussion of the values and preferences of the patient. (See <a class="local">'Subsequent management'</a> above and  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sarlis NJ, Gourgiotis L. Thyroid emergencies. Rev Endocr Metab Disord 2003; 4:129.</a></li><li><a class="nounderline abstract_t">Akamizu T, Satoh T, Isozaki O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 2012; 22:661.</a></li><li><a class="nounderline abstract_t">Akamizu T. Thyroid Storm: A Japanese Perspective. Thyroid 2018; 28:32.</a></li><li><a class="nounderline abstract_t">Galindo RJ, Hurtado CR, Pasquel FJ, et al. National Trends in Incidence, Mortality, and Clinical Outcomes of Patients Hospitalized for Thyrotoxicosis With and Without Thyroid Storm in the United States, 2004-2013. Thyroid 2019; 29:36.</a></li><li><a class="nounderline abstract_t">Swee du S, Chng CL, Lim A. Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis. Endocr Pract 2015; 21:182.</a></li><li><a class="nounderline abstract_t">Angell TE, Lechner MG, Nguyen CT, et al. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab 2015; 100:451.</a></li><li><a class="nounderline abstract_t">Ono Y, Ono S, Yasunaga H, et al. Factors Associated With Mortality of Thyroid Storm: Analysis Using a National Inpatient Database in Japan. Medicine (Baltimore) 2016; 95:e2848.</a></li><li><a class="nounderline abstract_t">Bourcier S, Coutrot M, Kimmoun A, et al. Thyroid Storm in the ICU: A Retrospective Multicenter Study. Crit Care Med 2020; 48:83.</a></li><li><a class="nounderline abstract_t">Kornelius E, Chang KL, Yang YS, et al. Epidemiology and factors associated with mortality of thyroid storm in Taiwan: a nationwide population-based study. Intern Emerg Med 2021; 16:601.</a></li><li><a class="nounderline abstract_t">Rivas AM, Larumbe E, Thavaraputta S, et al. Unfavorable Socioeconomic Factors Underlie High Rates of Hospitalization for Complicated Thyrotoxicosis in Some Regions of the United States. Thyroid 2019; 29:27.</a></li><li><a class="nounderline abstract_t">Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med 1996; 101:192.</a></li><li><a class="nounderline abstract_t">Maurer E, Vorländer C, Zielke A, et al. Short-Term Outcomes of Surgery for Graves' Disease in Germany. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Brooks MH, Waldstein SS. Free thyroxine concentrations in thyroid storm. Ann Intern Med 1980; 93:694.</a></li><li><a class="nounderline abstract_t">Ngo SY, Chew HC. When the storm passes unnoticed--a case series of thyroid storm. Resuscitation 2007; 73:485.</a></li><li><a class="nounderline abstract_t">Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006; 35:663.</a></li><li><a class="nounderline abstract_t">Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263.</a></li><li><a class="nounderline abstract_t">Ferrari SM, Fallahi P, Galetta F, et al. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord 2018; 19:325.</a></li><li><a class="nounderline abstract_t">Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. J Intensive Care Med 2015; 30:131.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Dalan R, Leow MK. Cardiovascular collapse associated with beta blockade in thyroid storm. Exp Clin Endocrinol Diabetes 2007; 115:392.</a></li><li><a class="nounderline abstract_t">Koh H, Kaushik M, Loh JK, Chng CL. Plasma exchange and early thyroidectomy in thyroid storm requiring extracorporeal membrane oxygenation. Endocrinol Diabetes Metab Case Rep 2019; 2019:1.</a></li><li><a class="nounderline abstract_t">Milner MR, Gelman KM, Phillips RA, et al. Double-blind crossover trial of diltiazem versus propranolol in the management of thyrotoxic symptoms. Pharmacotherapy 1990; 10:100.</a></li><li><a class="nounderline abstract_t">Cooper DS, Daniels GH, Ladenson PW, Ridgway EC. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med 1982; 73:867.</a></li><li><a class="nounderline abstract_t">Das G, Krieger M. Treatment of thyrotoxic storm with intravenous administration of propranolol. Ann Intern Med 1969; 70:985.</a></li><li><a class="nounderline abstract_t">Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). Endocr J 2016; 63:1025.</a></li><li><a class="nounderline abstract_t">Brunette DD, Rothong C. Emergency department management of thyrotoxic crisis with esmolol. Am J Emerg Med 1991; 9:232.</a></li><li><a class="nounderline abstract_t">Lee SY, Modzelewski KL, Law AC, et al. Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients. JAMA Netw Open 2023; 6:e238655.</a></li><li><a class="nounderline abstract_t">Cooper DS, Saxe VC, Meskell M, et al. Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab 1982; 54:101.</a></li><li><a class="nounderline abstract_t">Abuid J, Larsen PR. Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. J Clin Invest 1974; 54:201.</a></li><li><a class="nounderline abstract_t">Isozaki O, Satoh T, Wakino S, et al. Treatment and management of thyroid storm: analysis of the nationwide surveys: The taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm. Clin Endocrinol (Oxf) 2016; 84:912.</a></li><li><a class="nounderline abstract_t">Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180.</a></li><li><a class="nounderline abstract_t">Walter RM Jr, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med 1990; 88:69.</a></li><li><a class="nounderline abstract_t">Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid 1995; 5:403.</a></li><li><a class="nounderline abstract_t">Jongjaroenprasert W, Akarawut W, Chantasart D, et al. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid 2002; 12:627.</a></li><li><a class="nounderline abstract_t">Hodak SP, Huang C, Clarke D, et al. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 2006; 16:691.</a></li><li><a class="nounderline abstract_t">Kandil E, Khalek MA, Thethi T, et al. Thyroid storm in a patient with fulminant hepatic failure. Laryngoscope 2011; 121:164.</a></li><li><a class="nounderline abstract_t">Vyas AA, Vyas P, Fillipon NL, et al. Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosis. Endocr Pract 2010; 16:673.</a></li><li><a class="nounderline abstract_t">Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab 2004; 89:2142.</a></li><li><a class="nounderline abstract_t">Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am 2003; 32:519.</a></li><li><a class="nounderline abstract_t">Kinoshita H, Yasuda M, Furumoto Y, et al. Severe duodenal hemorrhage induced by Lugol's solution administered for thyroid crisis treatment. Intern Med 2010; 49:759.</a></li><li><a class="nounderline abstract_t">Park JM, Seok Lee I, Young Kang J, et al. Acute esophageal and gastric injury: complication of Lugol's solution. Scand J Gastroenterol 2007; 42:135.</a></li><li><a class="nounderline abstract_t">Tsatsoulis A, Johnson EO, Kalogera CH, et al. The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol 2000; 142:231.</a></li><li><a class="nounderline abstract_t">Mazzaferri EL, Skillman TG. Thyroid storm. A review of 22 episodes with special emphasis on the use of guanethidine. Arch Intern Med 1969; 124:684.</a></li><li><a class="nounderline abstract_t">Senda A, Endo A, Tachimori H, et al. Early administration of glucocorticoid for thyroid storm: analysis of a national administrative database. Crit Care 2020; 24:470.</a></li><li><a class="nounderline abstract_t">Solomon BL, Wartofsky L, Burman KD. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin Endocrinol (Oxf) 1993; 38:39.</a></li><li><a class="nounderline abstract_t">Kaykhaei MA, Shams M, Sadegholvad A, et al. Low doses of cholestyramine in the treatment of hyperthyroidism. Endocrine 2008; 34:52.</a></li><li><a class="nounderline abstract_t">Tsai WC, Pei D, Wang TF, et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Clin Endocrinol (Oxf) 2005; 62:521.</a></li><li><a class="nounderline abstract_t">Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf) 1988; 28:305.</a></li><li><a class="nounderline abstract_t">Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 1991; 35:439.</a></li><li><a class="nounderline abstract_t">Petry J, Van Schil PE, Abrams P, Jorens PG. Plasmapheresis as effective treatment for thyrotoxic storm after sleeve pneumonectomy. Ann Thorac Surg 2004; 77:1839.</a></li><li><a class="nounderline abstract_t">Koball S, Hickstein H, Gloger M, et al. Treatment of thyrotoxic crisis with plasmapheresis and single pass albumin dialysis: a case report. Artif Organs 2010; 34:E55.</a></li><li><a class="nounderline abstract_t">Muller C, Perrin P, Faller B, et al. Role of plasma exchange in the thyroid storm. Ther Apher Dial 2011; 15:522.</a></li><li><a class="nounderline abstract_t">Carhill A, Gutierrez A, Lakhia R, Nalini R. Surviving the storm: two cases of thyroid storm successfully treated with plasmapheresis. BMJ Case Rep 2012; 2012.</a></li><li><a class="nounderline abstract_t">Tieken K, Paramasivan AM, Goldner W, et al. THERAPEUTIC PLASMA EXCHANGE AS A BRIDGE TO TOTAL THYROIDECTOMY IN PATIENTS WITH SEVERE THYROTOXICOSIS. AACE Clin Case Rep 2020; 6:e14.</a></li></ol></div><div id="topicVersionRevision">Topic 7885 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766540" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thyroid emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22690898" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28899229" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyroid Storm: A Japanese Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30382003" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : National Trends in Incidence, Mortality, and Clinical Outcomes of Patients Hospitalized for Thyrotoxicosis With and Without Thyroid Storm in the United States, 2004-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25370315" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25343237" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886648" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Factors Associated With Mortality of Thyroid Storm: Analysis Using a National Inpatient Database in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31714398" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thyroid Storm in the ICU: A Retrospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32676839" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiology and factors associated with mortality of thyroid storm in Taiwan: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30526425" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Unfavorable Socioeconomic Factors Underlie High Rates of Hospitalization for Complicated Thyrotoxicosis in Some Regions of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8757360" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33322553" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Short-Term Outcomes of Surgery for Graves' Disease in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7212477" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Free thyroxine concentrations in thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17291668" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : When the storm passes unnoticed--a case series of thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127140" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thyrotoxicosis and thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325286" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Life-threatening thyrotoxicosis. Thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30242549" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thyroid disorders induced by checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23920160" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thyroid storm: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17701886" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiovascular collapse associated with beta blockade in thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31352696" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Plasma exchange and early thyroidectomy in thyroid storm requiring extracorporeal membrane oxygenation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349134" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Double-blind crossover trial of diltiazem versus propranolol in the management of thyrotoxic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6816067" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyperthyroxinemia in patients treated with high-dose propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5769631" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of thyrotoxic storm with intravenous administration of propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27746415" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1673341" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Emergency department management of thyrotoxic crisis with esmolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37067797" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6274892" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4134836" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387649" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment and management of thyroid storm: analysis of the nationwide surveys: The taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7054215" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Methimazole: an alternative route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2294767" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Rectal administration of propylthiouracil in the treatment of Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8563481" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193309" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889494" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intravenous methimazole in the treatment of refractory hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21120833" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thyroid storm in a patient with fulminant hepatic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439250" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126532" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rapid preoperative preparation for severe hyperthyroid Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12800544" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Perioperative management of the thyrotoxic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20424366" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Severe duodenal hemorrhage induced by Lugol's solution administered for thyroid crisis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190773" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acute esophageal and gastric injury: complication of Lugol's solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700716" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effect of thyrotoxicosis on adrenocortical reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4390923" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Thyroid storm. A review of 22 episodes with special emphasis on the use of guanethidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32727523" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Early administration of glucocorticoid for thyroid storm: analysis of a national administrative database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8435884" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adjunctive cholestyramine therapy for thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946743" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Low doses of cholestyramine in the treatment of hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15853819" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3168311" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1814659" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rapid preoperative preparation in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111206" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Plasmapheresis as effective treatment for thyrotoxic storm after sleeve pneumonectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20420590" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of thyrotoxic crisis with plasmapheresis and single pass albumin dialysis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22107688" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Role of plasma exchange in the thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23087271" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Surviving the storm: two cases of thyroid storm successfully treated with plasmapheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32984516" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : THERAPEUTIC PLASMA EXCHANGE AS A BRIDGE TO TOTAL THYROIDECTOMY IN PATIENTS WITH SEVERE THYROTOXICOSIS.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
